AYLA - AYLA STOCK NEWS

Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA) will participate in a "Fireside Chat" at the Jefferies Healthcare Conference from June 8-10, 2022, in New York, NY. The presentation is scheduled for June 10, 2022, from 12:15 PM to 12:40 PM EST at the Marriott Marquis. Ayala focuses on developing small molecule therapeutics for rare and aggressive cancers, using a bioinformatics platform and next-gen sequencing to target tumorigenic drivers. The webcast will be available on Ayala's website under the "Events and Presentations" section.

Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA) reported its first-quarter 2022 financial results, emphasizing continued progress in its clinical programs. Part A of the RINGSIDE study of AL102 in desmoid tumors has enrolled 42 patients, with initial interim data expected around mid-2022. Cash and cash equivalents stood at $27.4 million, down from $37.3 million at year-end 2021. Collaboration revenue decreased to $0.4 million from $1.0 million year-over-year. The net loss for the quarter was $10.0 million, with a loss per share of $0.66, compared to $9.6 million or $0.74 per share in Q1 2021.

Ayala Pharmaceuticals (Nasdaq: AYLA) announced that it will present a poster on AL101 during the 2022 ASCO Annual Meeting, scheduled for June 3-7 in Chicago. The poster will share results from the Phase 2 ACCURACY trial focusing on AL101's efficacy in patients with recurrent/metastatic adenoid cystic carcinoma (ACC) with Notch activating mutations. Currently, ACC has no approved standard treatments, highlighting the significance of AL101 as a potential therapy. The study will evaluate safety, efficacy, and pharmacokinetics of AL101 at different dosages.

Ayala Pharmaceuticals (Nasdaq: AYLA) has fully enrolled Part A of its Phase 2/3 RINGSIDE study for AL102 in desmoid tumors, with interim data expected by mid-2022. The company reported a 2021 net loss of $40.3 million, an increase from $30.1 million in 2020, with cash and equivalents at $37.3 million. R&D expenses rose to $29.9 million, reflecting the advancement of clinical studies. Positive preliminary data from the ACCURACY trial in adenoid cystic carcinoma were presented, and Ayala plans to initiate new trials in 2022 for multiple myeloma and T-cell acute lymphoblastic leukemia.

Ayala Pharmaceuticals (Nasdaq: AYLA) will present at the 32nd Annual Oppenheimer Healthcare Conference from March 15-17, 2022. This clinical-stage oncology company specializes in developing small molecule therapeutics aimed at rare and aggressive cancers, particularly in genetically defined populations. The company's presentation is scheduled for March 15, 2022, from 10:40 AM to 11:10 AM EDT. Additionally, Ayala will engage in one-on-one investor meetings at the event. More details can be found on their website.

Ayala Pharmaceuticals has initiated a “Window of Opportunity” study to evaluate AL101 in patients with advanced, Notch-activated Adenoid Cystic Carcinoma (ACC) before surgery. Conducted at M.D. Anderson Cancer Center, the study has enrolled its first five patients. AL101, a gamma-secretase inhibitor, has already shown monotherapy activity. Funded by the Department of Defense and others, the trial aims to assess AL101’s impact on tumor biology and improve patient outcomes by inhibiting the Notch pathway, which correlates with poorer prognosis in ACC.

Ayala Pharmaceuticals (Nasdaq: AYLA) announced the completion of patient enrollment for Part A of the Phase 2/3 RINGSIDE trial assessing AL102 in desmoid tumors. A total of 36 patients have been recruited to evaluate safety, tolerability, and tumor volume changes via MRI over 16 weeks. Interim results are expected by mid-2022, which will help determine the optimal dosing for the subsequent randomized phase. AL102 is a selective oral gamma-secretase inhibitor, representing a key development in treatment options for patients with this rare tumor type.

On January 6, 2022, Ayala Pharmaceuticals (Nasdaq: AYLA) announced its participation at the H.C. Wainwright BioConnect Virtual Conference, scheduled for January 10-13, 2022. The company, focused on small molecule therapeutics for rare and aggressive cancers, has two key candidates: AL101 and AL102. AL101 is in Phase 2 trials for Adenoid Cystic Carcinoma and Triple Negative Breast Cancer, while AL102 is in pivotal Phase 2/3 trials for desmoid tumors. The presentation will be available via webcast starting January 10, 2022, at 7:00 AM ET on Ayala's website.

Ayala Pharmaceuticals announced its strategic objectives for 2022, highlighting pivotal data read-outs from its clinical trials involving AL102 and AL101 in desmoid tumors and triple-negative breast cancer. The company aims to deliver significant clinical milestones this year, including the interim data from the Phase 2/3 RINGSIDE trial and the launch of a Phase 2 trial for AL101 in T-cell acute lymphoblastic leukemia. Ayala also reported completing a $25 million strategic equity financing in 2021, reinforcing its commitment to advancing its unique portfolio of gamma secretase inhibitors.